BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tod BM, Schneider JW, Bowcock AM, Visser WI, Kotze MJ. The tumor genetics of acral melanoma: What should a dermatologist know? JAAD Int 2020;1:135-47. [PMID: 34355205 DOI: 10.1016/j.jdin.2020.07.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Hsu C, Lee T, Lin M, Liao Y, Liau J, Sheen Y. Risk factors for lymphatic and hematogenous metastasis after diagnosis of cutaneous Melanoma in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.02.018] [Reference Citation Analysis]
2 Straker RJ 3rd, Krupp K, Sharon CE, Thaler AS, Kelly NJ, Chu EY, Elder DE, Xu X, Miura JT, Karakousis GC. Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. Ann Surg Oncol 2022. [PMID: 35301610 DOI: 10.1245/s10434-022-11478-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jamerson T, Rebecca VW, Aguh C. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review. J Natl Med Assoc 2021:S0027-9684(21)00186-3. [PMID: 34509302 DOI: 10.1016/j.jnma.2021.08.034] [Reference Citation Analysis]
4 Kurtansky NR, Manci RN, Bello DM, Adamson AS, Shoushtari AN, Wehner MR, Ariyan CE, Marghoob AA, Marchetti MA, Rotemberg V. Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma. Br J Dermatol 2022. [PMID: 35318644 DOI: 10.1111/bjd.21251] [Reference Citation Analysis]